Vanguard Personalized Indexing Management LLC Invests $249,000 in Denali Therapeutics Inc. (NASDAQ:DNLI)

Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) during the 2nd quarter, Holdings Channel reports. The fund purchased 10,790 shares of the company’s stock, valued at approximately $249,000.

Several other hedge funds have also recently bought and sold shares of the business. PNC Financial Services Group Inc. increased its holdings in shares of Denali Therapeutics by 48.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock valued at $53,000 after purchasing an additional 807 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Denali Therapeutics by 5.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company’s stock worth $613,000 after buying an additional 1,372 shares in the last quarter. Swiss National Bank boosted its stake in shares of Denali Therapeutics by 0.7% during the 1st quarter. Swiss National Bank now owns 218,200 shares of the company’s stock valued at $4,477,000 after buying an additional 1,500 shares during the period. GAMMA Investing LLC grew its holdings in shares of Denali Therapeutics by 879.5% during the 2nd quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock valued at $48,000 after acquiring an additional 1,847 shares in the last quarter. Finally, Arizona State Retirement System increased its stake in shares of Denali Therapeutics by 9.0% in the second quarter. Arizona State Retirement System now owns 33,114 shares of the company’s stock worth $769,000 after acquiring an additional 2,730 shares during the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Trading Up 0.5 %

NASDAQ DNLI opened at $29.43 on Monday. The company has a market cap of $4.20 billion, a P/E ratio of -30.66 and a beta of 1.37. Denali Therapeutics Inc. has a 1 year low of $14.56 and a 1 year high of $32.13. The company has a fifty day simple moving average of $25.44 and a 200 day simple moving average of $21.81.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.09. The business had revenue of $1.00 million during the quarter, compared to analyst estimates of $10.00 million. During the same period in the prior year, the business posted $1.30 earnings per share. The company’s revenue for the quarter was down 99.7% compared to the same quarter last year. Equities research analysts forecast that Denali Therapeutics Inc. will post -2.54 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DNLI has been the subject of a number of research reports. JPMorgan Chase & Co. lifted their price objective on Denali Therapeutics from $28.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Denali Therapeutics in a research note on Wednesday, September 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $35.00 price objective on shares of Denali Therapeutics in a research report on Monday, September 9th. Citigroup boosted their target price on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, Bank of America raised their price target on shares of Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $38.33.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.